Zobrazeno 1 - 10 of 18 pro vyhledávání: '"Kallappa M. Koti"'
1
A Simple Mantel–Haenszel Type Test for Noninferiority
Autor: Kallappa M. Koti
Publikováno v: Statistics in Biopharmaceutical Research. 13:113-118
Randomized clinical trials designed to establish noninferiority of an experimental therapy as compared to a standard (active-control) therapy as measured by binomial proportions are being widely us...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55c82cac128ac720ec2752d23ba36028
https://doi.org/10.1080/19466315.2020.1736140
Zobrazit plný text záznamu
2
New Generalized p-Value Approach for Noninferiority Analysis
Autor: Kallappa M. Koti
Publikováno v: Statistics in Biopharmaceutical Research. 8:35-39
The underlying statistical exercise in some noninferiority studies is to test a composite null hypothesis of a nonzero difference in the means of two normally distributed populations. These noninferiority studies are often analyzed under equal varian
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::98abcc334062e36a96d33581aa096805
https://doi.org/10.1080/19466315.2015.1093958
Zobrazit plný text záznamu
3
New Tests for Assessing Non-Inferiority and Equivalence from Survival Data
Autor: Kallappa M. Koti
Publikováno v: Open Journal of Statistics. :55-64
We propose a new nonparametric method for assessing non-inferiority of an experimental therapy compared to a standard of care. The ratio μE/μR of true median survival times is the parameter of interest. This is of considerable interest in clinical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e433608bb32e62413899119177e9e495
https://doi.org/10.4236/ojs.2013.32008
Zobrazit plný text záznamu
4
Exponential Failure-Time Mixture Model Approach for Validating KRAS as a Predictive Biomarker for Panitumumab Monotherapy in the Treatment of Metastatic Colorectal Cancer
Autor: Kallappa M. Koti
Publikováno v: Statistics in Biopharmaceutical Research. 3:425-433
Progression-free survival (PFS) results from the Amgen Study 20020408 were presented and discussed in the December 2008 Oncologic Drugs Advisory Committee. Using the retrospective “sorted” subgroup analyses it was claimed that Kirsten rat Sarcoma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47cc8f8e0f0ea1db5b9ec28cdfdc6f2b
https://doi.org/10.1198/sbr.2011.09034
Zobrazit plný text záznamu
5
Weibull Failure-Time Mixture Models for Evaluating Efficacy in the Presence of a Biomarker
Autor: Kallappa M. Koti
Publikováno v: Drug Information Journal. 43:585-593
A predictive marker is a marker that predicts the differential efficacy of a particular therapy based on marker status. Standard statistical methods compare treatments, not validate prediction. We propose a failure-time mixture model that achieves bo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::976616a58c6a644d803a13e07ba4ec54
https://doi.org/10.1177/009286150904300507
Zobrazit plný text záznamu
6
New Tests for Null Hypothesis of Non Unity Ratio of Proportions
Autor: Kallappa M. Koti
Publikováno v: Journal of Biopharmaceutical Statistics. 17:229-245
Testing for noninferiority and equivalence between an experimental therapy and a standard therapy in terms of the ratio of binomial proportions is considered. New tests based on the Fieller-Hinkley distribution of the ratio of random variables are pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64bc89d05eacbdba58237bb37c6c6930
https://doi.org/10.1080/10543400601177426
Zobrazit plný text záznamu
7
Gamma failure-time mixture models: yet another way to establish efficacy
Autor: Kallappa M. Koti
Publikováno v: Pharmaceutical Statistics. 2:133-144
We propose to use mixture survival models to establish the efficacy of the trial treatment. In particular, we consider the lognormal distribution to model the right-censored event time and a logistic regression for the incidence part of the model. Th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f97fc32d4686ac184deef7c40bbea96
https://doi.org/10.1002/pst.36
Zobrazit plný text záznamu
8
SOME INEQUALITIES IN HYPERGEOMETRIC FUNCTIONS USING STATISTICAL TECHNIQUES
Autor: KALLAPPA M. KOTI
Publikováno v: Proceedings of Indian National Science Academy, Vol 22, Iss 5 (2015)
SOME INEQUALITIES IN HYPERGEOMETRIC FUNCTIONS USING STATISTICAL TECHNIQUES
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::cee46c2c7a81512f6ca76e0484041f76
https://insa.nic.in/writereaddata/UpLoadedFiles/PINSA/20005a1e_389.pdf
Zobrazit plný text záznamu
9
Failure-Time Mixture Models: Yet Another Way to Establish Efficacy
Autor: Kallappa M. Koti
Publikováno v: Drug Information Journal. 35:1253-1260
We propose to use mixture survival models to establish the efficacy of the trial treatment. In particular, we consider the lognormal distribution to model the right-censored event time and a logistic regression for the incidence part of the model. Th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1da3a6b0ddfb9527f5baf0a3c77e03e5
https://doi.org/10.1177/009286150103500422
Zobrazit plný text záznamu
10
On a Primary Efficacy Endpoint
Autor: Kallappa M. Koti
Publikováno v: Drug Information Journal. 35:157-162
In some confirmatory clinical trials, data on the number of episodes of a particular type during baseline and treatment phase periods are collected. The primary efficacy variable proposed by the sponsor to compare the test drug with placebo is Y=(B -
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7106a46c123ad47ca995888de61f2f7b
https://doi.org/10.1177/009286150103500118
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje